Cerus Corporation (CERS)
NASDAQ: CERS · Real-Time Price · USD
1.510
+0.130 (9.42%)
At close: Jun 6, 2025, 4:00 PM
1.540
+0.030 (1.99%)
After-hours: Jun 6, 2025, 6:54 PM EDT
Cerus Revenue
Cerus had revenue of $43.24M in the quarter ending March 31, 2025, with 12.70% growth. This brings the company's revenue in the last twelve months to $185.14M, up 13.06% year-over-year. In the year 2024, Cerus had annual revenue of $180.27M with 15.29% growth.
Revenue (ttm)
$185.14M
Revenue Growth
+13.06%
P/S Ratio
1.52
Revenue / Employee
$293,879
Employees
630
Market Cap
288.65M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 180.27M | 23.90M | 15.29% |
Dec 31, 2023 | 156.37M | -5.68M | -3.51% |
Dec 31, 2022 | 162.05M | 31.19M | 23.83% |
Dec 31, 2021 | 130.86M | 38.94M | 42.36% |
Dec 31, 2020 | 91.92M | 17.27M | 23.14% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CERS News
- 4 days ago - Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - Business Wire
- 9 days ago - Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan - Business Wire
- 10 days ago - Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device - Business Wire
- 5 weeks ago - Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Cerus Corporation Announces First Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 - Business Wire
- 3 months ago - Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) - Business Wire
- 3 months ago - Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript - Seeking Alpha